Related Experiment Video
Updated: Jan 11, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
Published on: May 17, 2024
Optimizing blood pressure control in multimorbid hypertensive patients: insights from a real-world taiwanese cohort
Shao-Kai Sum1, Yu-Yen Ou2, Yao-Chang Wang3
1Department of Thoracic and Cardiovascular Surgery, Chang Gung Memorial Hospital, Linkou, Taoyuan.
Insights
Angiotensin II receptor blockers (ARBs) reduce mortality in Taiwanese patients with hypertension and cardiometabolic multimorbidity (CMM). Diuretics and vasodilators may increase risk, while optimal blood pressure control benefits those with CMM.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Current hypertension guidelines recommend ACE inhibitors (ACEi), ARBs, CCBs, and diuretics for patients with cardiometabolic multimorbidity (CMM).
- The effectiveness of these antihypertensive medications in Asian populations, particularly those with CMM, remains underexplored.
Purpose of the Study:
- To evaluate the association between different classes of antihypertensive medications and all-cause mortality in Taiwanese patients with hypertension and CMM.
- To assess the impact of systolic blood pressure (SBP) control and variability on mortality risk in this population.
Main Methods:
- A population-based cohort study utilizing Taiwan's administrative health databases from 2004 to 2014.
- Inclusion criteria: patients aged ≥20 years with hypertension and ≥8 outpatient blood pressure measurements.
- All-cause mortality was analyzed using inverse probability weighted Cox models, examining medication classes, adherence, and SBP control.
Main Results:
- Angiotensin II receptor blockers (ARBs) were associated with reduced mortality in patients with CMM (HR=0.80).
- Diuretics (HR=1.63) and vasodilators (HR=1.22) were linked to increased mortality risk; ACE inhibitors and CCBs showed neutral effects.
- Optimal SBP control (120-139 mmHg) benefited multimorbid patients, whereas intensive control (<120 mmHg) increased risk in less complex cases. High SBP variability also raised mortality risk.
Conclusions:
- The effectiveness of antihypertensive medications varies significantly based on the burden of cardiometabolic multimorbidity.
- ARBs demonstrate a mortality-reducing benefit in multimorbid patients, contrasting with potential risks associated with diuretics and vasodilators.
- Optimal SBP control is crucial for patients with CMM, but intensive blood pressure lowering may pose risks in less complex hypertensive individuals.
Objective:
Guidelines from ACC/AHA, ESC/ESH, and JNC 8 recommend ACE inhibitors (ACEi), ARBs, calcium channel blockers (CCBs), and diuretics for hypertension in patients with cardiometabolic multimorbidity (CMM). Their effectiveness in Asians is underexplored. This study evaluates their association with mortality in Taiwanese patients with hypertension and CMM.
Methods:
A population-based cohort study was conducted using Taiwan's administrative health databases (2004-2014). Patients aged ≥20 years with hypertension and ≥8 outpatient blood pressure measurements were included. All-cause mortality was assessed using inverse probability weighted Cox models, evaluating medication classes, adherence, and systolic blood pressure (SBP) control.
Results:
Of 80 748 patients (mean age 60 years, 56.3% male), 41.7% had one CMM, and 9.4% had multiple CMMs. ARBs reduced mortality in multimorbid patients [hazard ratio (HR) = 0.80, 95% confidence interval (CI) 0.67-0.95], while diuretics (HR = 1.63, 95% CI 1.33-1.99) and vasodilators (HR = 1.22, 95% CI 1.03-1.45) increased risk. ACEi and CCBs were neutral. Optimal SBP control (120-139 mmHg) benefited multimorbid patients, but intensive control (<120 mmHg) increased risk in those with ≤1 CMM (HR = 1.37, 95% CI 1.20-1.55). High SBP variability (SD >18 mmHg) raised mortality risk (HR = 1.62, 95% CI 1.07-2.44).
Conclusions:
Antihypertensive effectiveness varies by CMM burden. ARBs reduce mortality in multimorbid patients, while diuretics and vasodilators may increase risk. Optimal SBP control (120-139 mmHg) benefits multimorbid patients, but intensive control may harm less complex cases. Further research is needed.
Related Concept Videos
Hypertension IV: Drug Therapy and Lifestyle Modifications
Hypertension V: Nursing Management
Hypertension and Regulation of Blood Pressure
Hypertension III: Clinical Manifestations and Diagnostic Studies
Errors occurring during blood pressure monitoring
Several factors...
Hypertension II: Pathophysiology

